Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Danaher Corp (NY: DHR )

204.23 -0.73 (-0.36%)
Streaming Delayed Price Updated: 3:57 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Danaher Corp

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Wednesday's pre-market session: top gainers and losers in the S&P500 index
Pre-market stock analysis of S&P500 stocks on 2025-01-29: top gainers and losers in today's session. 
Via Chartmill
Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Danaher Q4: EPS Miss Expectations Amid Diagnostics Segment Lag
Danaher's Q4 earnings missed expectations due to a decline in its diagnostics segment, despite stronger sales in biotechnology and life sciences. 
Via Benzinga
Topics Earnings
Exposures Financial
Jim Cramer Recommends Buying 'Fabulous' BlackRock, Calls Coterra Energy The 'Cheapest' Natural Gas Company
Cramer comments on Danaher, Coterra, BlackRock and Digital Realty. As for Grail, "Just great science, but it is parabolic," he adds. 
Via Benzinga
Topics Energy
Exposures Fossil Fuels
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years
Via Benzinga
Earnings Scheduled For January 29, 2025
Via Benzinga
Danaher Unusual Options Activity
Via Benzinga
14 Analysts Have This To Say About Danaher
Via Benzinga
3 Insanely Cheap Stocks to Buy
The object is to buy low and sell high. 
Via The Motley Fool
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely. 
Via Benzinga
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
From Aldevron
Via Business Wire
5 High-Flying Stocks In Dan Loeb's Portfolio: Cinemark, Corpay, Amazon Lead
Dan S. Loeb, founder of Third Point, a $7B hedge fund, is known for bold activist strategies that drive transformation in global companies. 
Via Benzinga
What the Options Market Tells Us About Danaher
Via Benzinga
What the Options Market Tells Us About Danaher
Via Benzinga
Peering Into Danaher's Recent Short Interest
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and the reasons why the stocks may be drawing attention. 
Via Benzinga
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA upgrades Danaher and Revvity, predicting a mixed but improving outlook for life sciences tools in fiscal year 2025 amid ongoing market challenges. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Inquiry Into Danaher's Competitor Dynamics In Life Sciences Tools &amp; Services Industry
Via Benzinga
A Look Into Danaher Inc's Price Over Earnings
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,600 Today
Via Benzinga
Critical Insights From Danaher Analyst Ratings: What You Need To Know
Via Benzinga
Want to Grow a Passive Income Snowball? Buy These 7 Elite Dividend Growth Stocks.
These seven companies are transforming steady profits into rising passive income streams for investors. 
Via The Motley Fool
Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
Danaher posts Q3 sales of $5.79 billion, surpassing expectations. 2024 guidance includes bioprocessing revenue decline and Cepheid respiratory sales of $1.7 billion. 
Via Benzinga
Stocks Fall, GM Eyes Best Day In A Year, Gold Breaks Records, Silver Hits 12-Year Highs: What's Driving Markets Tuesday?
Wall Street traded lower for the second consecutive day on Tuesday, as investor sentiment turned cautious with the U.S. presidential election just two weeks away. Concerns over U.S. fiscal policies and... 
Via Benzinga
A Closer Look at Danaher's Options Market Dynamics
Via Benzinga
Life Science Giant Danaher Q3 Earnings: Revenue And EPS Beat, Sticks To Annual Guidance
Danaher posted third-quarter sales of $5.8 billion, surpassing expectations, with growth in life sciences and diagnostics segments, and a 27.5% operating margin. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.